Clinical-stage Immunotherapy Memgen is a clinical-stage biotech developing viral immunotherapies with MEM40 across cancer and infectious disease indications, presenting multiple collaboration and co-development opportunities for biotech partners and larger pharma seeking to augment immunotherapy portfolios.

MemVax Adjuvant Opportunity MemVax is a versatile vaccine adjuvant with a readiness of over 100,000 doses and an active FDA file, offering potential collaboration or licensing for partners aiming to enhance vaccines across various delivery platforms.

Strategic Cancer Collaboration Lead candidate MEM-288 is in advanced NSCLC with a collaboration alongside Moffitt Cancer Center, signaling a track record of academic partnerships and opportunities for co development, out-licensing, or trial expansion in oncology.

Small but Specialized Memgen operates with a lean team and substantial R&D assets, making it an attractive partner for specialized biotech stacks seeking nimble collaboration, joint ventures, or milestone-based deals with clear value delivery.

Funding and Growth Potential With reported revenue in the low to mid single digits and total funding around $30M, Memgen presents a viable entry point for strategic investors or pharma-aligned capital partnerships to accelerate late-stage trials and expand manufacturing.